NASDAQ:MRKR

Marker Therapeutics Q2 2025 Earnings Results & Report

Marker Therapeutics logo
$0.85 +0.02 (+1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$0.85 +0.00 (+0.09%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.29 versus the -$0.55 consensus estimate, while revenue of $860 thousand topped the $723 thousand estimate by $137 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Marker Therapeutics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.26
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Marker Therapeutics Revenue Results

Actual Revenue
$860 thousand
Expected Revenue
$723 thousand
Beat/Miss
Beat by +$137.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

Marker Therapeutics Q2 2025 Earnings FAQ

Marker Therapeutics (NASDAQ:MRKR) reported earnings of -$0.29 per share for Q2 2025, beating the consensus estimate of -$0.55. The report was announced on Thursday, August 14, 2025.

Marker Therapeutics reported revenue of $860 thousand for Q2 2025, against a consensus estimate of $723 thousand.

Marker Therapeutics Earnings Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Marker Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email.

About Marker Therapeutics

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen.

The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies. These candidates are investigational and remain in clinical development.

Marker Therapeutics was formed in 2018 through a merger involving TapImmune and Marker Therapeutics (NASDAQ:MRKR); TapImmune subsequently adopted the Marker Therapeutics name. The company is based in Houston, Texas, and its development work centers on advancing cell-based cancer treatments.

View Marker Therapeutics Profile